| Literature DB >> 27556391 |
Nuno Morais1, Joana Cruz2, Alda Marques2.
Abstract
BACKGROUND: There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).Entities:
Mesh:
Year: 2016 PMID: 27556391 PMCID: PMC5015673 DOI: 10.1590/bjpt-rbf.2014.0162
Source DB: PubMed Journal: Braz J Phys Ther ISSN: 1413-3555 Impact factor: 3.377
Socio-demographic and clinical characteristics of patients with COPD and healthy controls.
|
|
|
| |
|---|---|---|---|
| Age ( | 67.93±9.71 | 66.80±7.47 | 0.72 |
| Gender
( | 13 (86.7%) | 7 (46.7%) | 0.05 |
| Height
( | 166.00±6.18 | 160.87±8.58 | 0.07 |
| Weight
( | 77.37±17.95 | 72.47±10.39 | 0.37 |
| BMI
( | 28.00±5.87 | 28.01±3.30 | 0.99 |
| FEV1 | |||
| Value
( | 1.72±0.52 | 2.27±0.53 | 0.01 |
| % pred | 66.00±17.77 | 100.67±14.90 | <0.01 |
| FVC | |||
| Value
( | 2.57±0.77 | 2.58±0.62 | 0.97 |
| % pred | 75.33±17.78 | 91.53±14.74 | 0.01 |
| GOLD grade, n (%) | |||
| Mild COPD | 2 (13.3%) | - | |
| Moderate COPD | 11 (73.4%) | - | |
| Severe-to-very-severe COPD | 2 (13.3%) | - | |
| Respiratory medication, n(%) | |||
| Long-acting beta2-agonists | 1 (6.67%) | - | |
| Short-acting beta2-agonists | 3 (20.00%) | - | |
| Long-acting anticholinergics | 4 (26.67%) | - | |
| Inhaled corticosteroids | 1 (6.67%) | - | |
| Combination of long-acting beta2-agonist plus corticosteroids | 4 (26.67%) | - |
Values are shown as mean±SD, unless otherwise indicated. BMI: body mass index; FEV1: forced expired volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; % pred: percentage predicted.
Significant at p<0.05.
Alignment and mobility of the head, thoracic spine and shoulder, and pectoralis minor muscle length of patients with COPD and healthy controls.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Head | Neutral position | 45.54±9.16 | 43.16±4.72 | 2.38 [–3.07 to 7.83] | 0.38 | 0.33 | 0.14 |
| Maximal protraction | 28.81±7.30 | 35.91±8.56 | –7.09 [–13.0 to -1.15] | 0.02 | 0.89 | 0.65 | |
| Maximal retraction | 50.62±8.62 | 47.17±9.83 | 3.46 [–3.46 to 10.37] | 0.31 | 0.37 | 0.16 | |
| Total mobility | 21.81±10.42 | 13.40±7.84 | 8.42 [1.52 to 15.31] | 0.02 | 0.91 | 0.67 | |
| Upper thoracic spine | Neutral position | 21.68±6.88 | 22.58±4.58 | –0.90 [–5.27 to 3.47] | 0.68 | 0.15 | 0.07 |
| Maximal flexion | 36.49±8.62 | 40.42±8.17 | –3.93 [–10.22 to 2.35] | 0.21 | 0.47 | 0.24 | |
| Maximal extension | 13.13±7.05 | 17.01±7.23 | –3.87 [–9.21 to 1.47] | 0.15 | 0.54 | 0.30 | |
| Total mobility | 23.35±10.28 | 23.41±10.64 | –0.06 [–7.88 to 7.77] | 0.99 | 0.01 | 0.05 | |
| Lower thoracic spine | Neutral position | –10.73±6.78 | –8.82±4.13 | -1.91 [-6.11 to 2.29] | 0.36 | 0.34 | 0.15 |
| Maximal flexion | –2.00±9.64 | 0.95±7.31 | -2.95 [-9.35 to 3.46] | 0.35 | 0.34 | 0.15 | |
| Maximal extension | -14.82±7.28 | –11.61±4.31 | –3.22 [–7.69 to 1.26] | 0.15 | 0.54 | 0.30 | |
| Total mobility | 12.83±7.86 | 12.55±7.47 | 0.27 [–5.46 to 6.01] | 0.92 | 0.04 | 0.05 | |
| Thoracic kyphosis | Neutral position | 33.08±8.65 | 31.40±6.90 | 1.67 [–4.18 to 7.52] | 0.56 | 0.21 | 0.09 |
| Maximal flexion | 44.01±11.50 | 46.50±9.47 | –2.49 [–10.37 to 5.38] | 0.52 | 0.24 | 0.10 | |
| Maximal extension | 28.00±9.05 | 28.61±9.67 | –0.61 [–7.62 to 6.39] | 0.86 | 0.07 | 0.05 | |
| Total mobility | 16.01±14.22 | 17.99±12.31 | –1.98 [–11.93 to 7.96] | 0.69 | 0.15 | 0.07 | |
| Shoulder joint | Maximal flexion | 136.71±11.91 | 149.08±11.58 | –12.37 [–21.16 to –3.58] | 0.01 | 1.05 | 0.79 |
|
| Dominant | 16.51±1.50 | 15.91±1.36 | 0.61 [–0.47 to 1.68] | 0.26 | 0.42 | 0.20 |
| Non-dominant | 16.77±1.75 | 15.65±1.44 | 1.13 [–0.07 to 2.32] | 0.06 | 0.70 | 0.46 |
Values are shown as mean±SD, unless otherwise indicated. PmM: Pectoralis minor muscle; 95% CI: 95% confidence intervals.
Significant at p<0.05.
Thoracic circumference at peak inspiration and expiration and thoracic excursion, measured at the upper and lower thorax, in patients with COPD and healthy controls.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
| Thoracic circumference at PI | 104.32±10.62 | 100.94±6.15 | 3.38 [–3.11 to 9.87] | 0.30 | 0.39 | 0.18 |
| Thoracic circumference at PE | 101.97±11.24 | 98.33±5.72 | 3.64 [–3.03 to 0.31] | 0.27 | 0.41 | 0.19 |
| Thoracic excursion | 2.35±1.38 | 2.61±1.06 | –0.26 [–1.18 to 0.66] | 0.57 | 0.21 | 0.09 |
|
| ||||||
| Thoracic circumference at PI | 101.46±11.17 | 97.94±5.25 | 3.52 [–3.13 to 10.16] | 0.28 | 0.40 | 0.18 |
| Thoracic circumference at PE | 98.59±11.72 | 94.32±4.82 | 4.27 [–2.59 to 11.13] | 0.21 | 0.48 | 0.25 |
| Thoracic excursion | 2.86±1.24 | 3.62±1. | –0.75 [–1.85 to 0.35] | 0.17 | 0.52 | 0.28 |
Values are shown as mean±SD, unless otherwise indicated. PI: peak inspiration; PE: peak expiration; 95% CI: 95% confidence intervals.
Predictors of FEV1 (Liters) in patients with COPD and healthy controls, using multiple regression analysis.
|
|
|
| |
|---|---|---|---|
|
| |||
| Non-dominant PmM length | 0.193 [0.065 to 0.320] | 0.652 | 0.01 |
| Maximal head protraction | 0.038 [0.007 to 0.068] | 0.534 | 0.01 |
|
| |||
| Thoracic circumference of the lower thorax at PI | 0.070 [0.041 to 0.099] | 0.688 | <0.01 |
| Head posture in neutral position | 0.100 [0.058 to 0.143] | 0.890 | <0.01 |
| Upper thoracic spine at maximal extension | –0.041 [–0.069 to –0.014] | –0.562 | 0.01 |
Patients with COPD: Constant=-2.602. F(2,12)=7.464; p=0.01; r2=0.55; r2 adjusted=0.34. Healthy controls: Constant=-8.170; F(3,11)=16.660; p<0.01; r2=0.82; r2 adjusted=0.68. PI: peak inspiration; PmM: Pectoralis minor muscle; FEV1 : Forced Expired Volume in the First second.
Predictors of FVC (Liters) in patients with COPD and healthy controls, using a multiple regression analysis.
|
|
|
| |
|---|---|---|---|
|
| |||
| Non-dominant PmM length | 0.423 [0.287 to 0.560] | 0.958 | <0.01 |
| Upper thoracic spine at maximal flexion | 0.045 [0.022 to 0.069] | 0.505 | <0.01 |
| Maximal head protraction | 0.047 [0.018 to 0.076] | 0.441 | 0.01 |
| Thoracic kyphosis at maximal extension | 0.033 [0.007 to 0.058] | 0.382 | 0.02 |
|
| |||
| Thoracic circumference of the lower thorax at PI | 0.090 [0.056 to 0.123] | 0.761 | <0.01 |
| Head posture in neutral position | 0.101 [0.051 to 0.151] | 0.770 | 0.01 |
| Upper thoracic spine at maximal extension | –0.043 [–0.075 to –0.010] | –0.498 | 0.01 |
Patients with COPD: Constant=–8.442. F(4,10)=17.044; p<0.01; r2=0.87, r2 adjusted=0.72. Healthy controls: Constant=–9.835. F(3,11)=16.633; p<0.01; r2=0.82; r2 adjusted=0.68. PI: peak inspiration; PmM: Pectoralis minor muscle; FVC: Forced Vital Capacity.